Denali Therapeutics Inc.

NasdaqGS:DNLI 주식 보고서

시가총액: US$3.9b

Denali Therapeutics 과거 수익 실적

과거 기준 확인 0/6

Denali Therapeutics의 수입은 연평균 -19.3%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 19%의 비율로 증가했습니다. 매출은 연평균 13.6%의 비율로 증가해 왔습니다.

주요 정보

-19.3%

수익 성장률

-11.1%

EPS 성장률

Biotechs 산업 성장17.0%
매출 성장률13.6%
자기자본 수익률-30.3%
순이익-33,121.9%
최근 수익 업데이트30 Jun 2024

최근 과거 실적 업데이트

Recent updates

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Aug 20

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Jul 26
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%

May 23
Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

May 13

An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued

Apr 17
An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Mar 21
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Mar 07

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Feb 21
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

Jan 26
Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Nov 20
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

Oct 09
Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Aug 22
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price

May 02
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price

Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be

Mar 04
Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be

Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation

Feb 06
Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation

These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat

Nov 09
These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat

Denali Therapeutics proposes $250M stock offering; shares down 6% post market

Oct 18

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Oct 12
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122

Oct 10

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

Jun 08
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate

수익 및 비용 분석

Denali Therapeutics 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

NasdaqGS:DNLI 수익, 비용 및 수입 (USD Millions )
날짜수익수익G+A 비용R&D 비용
30 Jun 241-420101-27
31 Mar 24295-1371010
31 Dec 23331-1451030
30 Sep 23341-124102194
30 Jun 23343-128100194
31 Mar 23101-371950
31 Dec 22108-326900
30 Sep 22111-303890
30 Jun 22112-284850
31 Mar 2283-286830
31 Dec 2149-291790
30 Sep 2135330750
30 Jun 2135756720
31 Mar 2134058670
31 Dec 2033671600
30 Sep 2024-228530
30 Jun 2028-216490
31 Mar 2026-215500
31 Dec 1927-198460
30 Sep 19148-66470
30 Jun 19135-55440
31 Mar 19133-52360
31 Dec 18129-36320
30 Sep 183-137260
30 Jun 182-123210
31 Mar 181-91180
31 Dec 170-88160
30 Sep 170-851417
30 Jun 170-931339
31 Mar 170-901255
31 Dec 160-87120

양질의 수익: DNLI 은(는) 현재 수익성이 없습니다.

이익 마진 증가: DNLI 은(는) 현재 수익성이 없습니다.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: DNLI 은(는) 수익성이 없으며 지난 5년 동안 연간 19.3% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 DNLI 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: DNLI 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -2.3% )와 비교하기 어렵습니다.


자기자본 수익률

높은 ROE: DNLI 현재 수익성이 없기 때문에 마이너스 자본 수익률( -30.26% )을 갖습니다.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기